Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Recent years have brought a more targeted approach to treating acute myeloid leukemia (AML) based on accumulating knowledge about the genetic makeup of the heterogenous disease. “Over the past decade, ...

PRESS RELEASEAB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Panelists discuss how social determinants of health significantly impact AML care, particularly regarding transportation access, health literacy, and the intensive nature of treatment requiring ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...

OHSU researchers found that combining venetoclax with breast cancer drug palbociclib strongly improves AML treatment by ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

SAN DIEGO and TORONTO - Aptose Biosciences (NASDAQ:APTO) Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company specializing in precision oncology with a current market capitalization of $8.79 ...

DUBLIN--(BUSINESS WIRE)--The "Global Acute Myeloid Leukemia (AML) Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering. The global AML treatment market was ...

Acute myeloid leukemia (AML) is a cancer of the bone marrow and blood. It is also called acute myelogenous leukemia or acute myelocytic leukemia. It happens when some of your blood stem cells stop ...

Acute Myeloid Leukemia (AML) is increasingly affecting Indians in their 30s and 40s, with experts warning of delayed diagnoses and limited access to treatment. Only 30% of patients receive definitive ...